Sarah Knerr1, Boya Guo1, Kathleen F Mittendorf2, Heather Spencer Feigelson3, Marian J Gilmore2, Gail P Jarvik4, Tia L Kauffman5, Erin Keast5, Frances L Lynch5, Kristin R Muessig2, Sonia Okuyama6, David L Veenstra7, Jamilyn M Zepp2, Katrina A B Goddard2, Beth Devine7. 1. School of Public Health, University of Washington, Washington, Seattle, USA. 2. Department of Translational and Applied Genomics, Center for Health Research, Kaiser Permanente Northwest, Oregon, Portland, USA. 3. Institute for Health Research, Kaiser Permanente, Denver, Colorado, USA. 4. School of Medicine, University of Washington, Washington, Seattle, USA. 5. Center for Health Research, Kaiser Permanente Northwest, Oregon, Portland, USA. 6. Division of Oncology, Denver Health and Hospital Authority, Denver, Colorado, USA. 7. The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Washington, Seattle, USA.
Abstract
BACKGROUND: Germline genetic testing enables primary cancer prevention, including through prophylactic surgery. We examined risk-reducing surgeries in unaffected individuals tested for hereditary cancer susceptibly between 2010 and 2018 in the Kaiser Permanente Northwest health system. METHODS: We used an internal genetic testing database to create a cohort of individuals who received tests including one or more high-penetrance hereditary cancer susceptibility gene. We then identified, after testing, bilateral mastectomy, bilateral salpingo-oophorectomy (BSO), and total hysterectomy procedures in electronic health record and claims data through 2019. We describe surgery utilization by genetic test results and National Comprehensive Cancer Network (NCCN) guidelines. RESULTS: The cohort included 1020 individuals, 16% with pathogenic/likely pathogenic (P/LP) variants in one or more of the following genes: BRCA1, BRCA2, CHEK2, APC, MUTYH, ATM, MSH2, PALB2, BRIP1, MLH1, MSH6, EPCAM, FLCN, RAD51C, RAD51D, or TP53. Among individuals with P/LP variants making them candidates for mastectomy, BSO, or hysterectomy per NCCN guidelines, 34% (33/97), 24% (23/94), and 8% (1/12), respectively, underwent surgery during follow-up. Fifty-three percent (18/37) of hysterectomies were among APC, BRCA1, and BRCA2 P/LP variant heterozygotes, typically concurrent with BSO. Three individuals with variants of uncertain significance (only) and 22 with negative results had prophylactic surgery after genetic testing. CONCLUSIONS: Uptake of risk-reducing surgery following usual care genetic testing appears to be lower than in studies that actively recruit high-risk patients and provide testing and follow-up care in specialized settings. Factors in addition to genetic test results and NCCN guidelines motivate prophylactic surgery use and deserve further study.
BACKGROUND: Germline genetic testing enables primary cancer prevention, including through prophylactic surgery. We examined risk-reducing surgeries in unaffected individuals tested for hereditary cancer susceptibly between 2010 and 2018 in the Kaiser Permanente Northwest health system. METHODS: We used an internal genetic testing database to create a cohort of individuals who received tests including one or more high-penetrance hereditary cancer susceptibility gene. We then identified, after testing, bilateral mastectomy, bilateral salpingo-oophorectomy (BSO), and total hysterectomy procedures in electronic health record and claims data through 2019. We describe surgery utilization by genetic test results and National Comprehensive Cancer Network (NCCN) guidelines. RESULTS: The cohort included 1020 individuals, 16% with pathogenic/likely pathogenic (P/LP) variants in one or more of the following genes: BRCA1, BRCA2, CHEK2, APC, MUTYH, ATM, MSH2, PALB2, BRIP1, MLH1, MSH6, EPCAM, FLCN, RAD51C, RAD51D, or TP53. Among individuals with P/LP variants making them candidates for mastectomy, BSO, or hysterectomy per NCCN guidelines, 34% (33/97), 24% (23/94), and 8% (1/12), respectively, underwent surgery during follow-up. Fifty-three percent (18/37) of hysterectomies were among APC, BRCA1, and BRCA2 P/LP variant heterozygotes, typically concurrent with BSO. Three individuals with variants of uncertain significance (only) and 22 with negative results had prophylactic surgery after genetic testing. CONCLUSIONS: Uptake of risk-reducing surgery following usual care genetic testing appears to be lower than in studies that actively recruit high-risk patients and provide testing and follow-up care in specialized settings. Factors in addition to genetic test results and NCCN guidelines motivate prophylactic surgery use and deserve further study.
Authors: Mary B Daly; Robert Pilarski; Matthew B Yurgelun; Michael P Berry; Saundra S Buys; Patricia Dickson; Susan M Domchek; Ahmed Elkhanany; Susan Friedman; Judy E Garber; Michael Goggins; Mollie L Hutton; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison W Kurian; Christine Laronga; Jennifer K Litton; Julie S Mak; Carolyn S Menendez; Sofia D Merajver; Barbara S Norquist; Kenneth Offit; Tuya Pal; Holly J Pederson; Gwen Reiser; Kristen Mahoney Shannon; Kala Visvanathan; Jeffrey N Weitzel; Myra J Wick; Kari B Wisinski; Mary A Dwyer; Susan D Darlow Journal: J Natl Compr Canc Netw Date: 2020-04 Impact factor: 11.908
Authors: Marc D Schwartz; Claudine Isaacs; Kristi D Graves; Elizabeth Poggi; Beth N Peshkin; Christy Gell; Clinton Finch; Scott Kelly; Kathryn L Taylor; Lauren Perley Journal: Cancer Date: 2011-06-29 Impact factor: 6.860
Authors: Kathleen M Schmeler; Henry T Lynch; Lee-may Chen; Mark F Munsell; Pamela T Soliman; Mary Beth Clark; Molly S Daniels; Kristin G White; Stephanie G Boyd-Rogers; Peggy G Conrad; Kathleen Y Yang; Mary M Rubin; Charlotte C Sun; Brian M Slomovitz; David M Gershenson; Karen H Lu Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: Jennifer M Weiss; Samir Gupta; Carol A Burke; Lisen Axell; Lee-May Chen; Daniel C Chung; Katherine M Clayback; Susan Dallas; Seth Felder; Olumide Gbolahan; Francis M Giardiello; William Grady; Michael J Hall; Heather Hampel; Rachel Hodan; Gregory Idos; Priyanka Kanth; Bryson Katona; Laura Lamps; Xavier Llor; Patrick M Lynch; Arnold J Markowitz; Sara Pirzadeh-Miller; Niloy Jewel Samadder; David Shibata; Benjamin J Swanson; Brittany M Szymaniak; Georgia L Wiesner; Andrew Wolf; Matthew B Yurgelun; Mae Zakhour; Susan D Darlow; Mary A Dwyer; Mallory Campbell Journal: J Natl Compr Canc Netw Date: 2021-10-15 Impact factor: 11.908
Authors: Sukh Makhnoon; Grace Tran; Brooke Levin; Kristin D Mattie; Brian Dreyer; Robert J Volk; Generosa Grana; Banu K Arun; Susan K Peterson Journal: Cancer Date: 2021-06-22 Impact factor: 6.860